RE:RE:RE:Over-reaction reflected in Share Price DropQ1 financials are due in one month and can help clear up the profit issue enhanced by the fall in the Canadian dollar. He has to make the rounds and convince the market of this after the news, and show he can get the money, and clients are still on side:
"Mr. Gagnon added, "We are very pleased with the advancements we have made over the last year and the momentum we have built preparing the company for its next stage of growth. We are more confident than ever that Ceapro has the key to new successes by offering: a de-risked business model with a base business in the cosmetic sector, which provides a revenue stream; well advanced near-term catalysts with dry beta glucan as a potential functional food/nutraceutical; and long-term catalysts with dry formulations of avenanthramides for the nutraceutical and/or pharmaceutical markets. Also, we view the development of our proprietary PGX platform technology for which we have recently obtained the worldwide rights for all industrial applications as a game changer for Ceapro."
"We have moved our offices and research laboratories to our new site in 2014. While the successful completion, implementation and commissioning of the production area remains our top priority for 2015, in parallel, we are committed to remain laser focused on executing our strategic imperatives for growth that should drive significant value to all of our shareholders," concluded Mr. Gagnon."
Read more at https://www.stockhouse.com/news/press-releases/2015/04/22/ceapro-reports-record-full-year-2014-financial-results#ishi3d7ftftoXbv5.99